Weekly roundup: A week of deals for Optimum clients despite turbulent markets
Poolbeg Pharma plc completed a successful, upsized and oversubscribed fundraising to raise total gross proceeds of £4.865 million
Poolbeg Pharma conditionally raised £4.865 million following the placing of 134.8 million new Ordinary Shares, raising gross proceeds of £3.370 million, the subscription of 53.8 million new Ordinary Shares, raising gross proceeds of £1.345 million, and an oversubscribed retail offer that was upsized and raised £150,000. The Company will use the proceeds to fund a Phase 2a clinical trial for POLB 001, targeting prevention of cancer immunotherapy-induced Cytokine Release Syndrome (CRS), and a proof-of-concept clinical trial for its Oral GLP-1. Its cash runway has also been extended through to 2027.
Novo Nordisk Foundation enters into strategic framework agreement with the World Health Organization (WHO) to advance global health
At the 78th World Health Assembly in Geneva, the Novo Nordisk Foundation has pledged up to DKK 380 million to the WHO for the period 2025-2028. The Foundation and WHO are deepening the partnership, adopting a more strategic approach through the signature of a framework agreement that will enable the two organisations to accelerate progress by working together.
🔥 Hot topic
👥Industry events
Optimum’s 17th Annual Healthcare Conference
It is now less than five months until Optimum’s 17th Annual Healthcare Conference 2025! Returning to the King’s Fund this autumn, this prestigious invitation-only event brings together investors and executives from across the life sciences sector, register your interest today.
That’s all folks! To stay in the know – subscribe to Optimum’s weekly wrap-up today!
